The euphoria from this news announcement isn’t l

The euphoria from this news announcement isn’t looking at the fine print of the trial design of the study. Recruitment required at least one underlying medical condition like obesity, old age (>60 years), diabetes, or heart disease. Looking at this patient population was needed to obtain statistical significance because too many with no underlying conditions just get better on their own. The trial could have been a failure otherwise. Another factor contributing to Merck's success is a smaller than expected stratification of Delta variant infections. Only 40% of the clinical trial had Delta variant patients. People need to consider that a majority of the data was from the alpha variant which means that if Merck doesn't segregate the data by variant they are trying to pull the wool over our eyes to hide how weak the data really is.

Merck also took precautions to go after the unvaccinated population. Now Pfizer's drug is following in the same footsteps going after the unvaccinated with at least one underlying medical condition. Todos Medical's drug Tollovir doesn't have any of these exclusion criteria in their clinical trial which is probably why it’s the best in class of the oral antivirals. Ironically it's available right now if you don't mind reverse engineering the dosage and taking a couple of pills.

https://www.zerohedge.com/news/2021-10-01/mer...is-removal